SCHEMBL13216630

SCHEMBL13216630

N#Cc1cccc(C2(CC(=O)N3CC(O)C3)C3CC4CC2CC(C3)C4O)c1

nearest known ligand 0.77

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 20/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13317389 0.92 HSD11B1 (0.64) HSD11B1
SCHEMBL13237073 0.87 HSD11B1 (1.00) HSD11B1
SCHEMBL13216623 0.86 HSD11B1 (1.00) HSD11B1
SCHEMBL13216724 0.84 HSD11B1 (0.78) HSD11B1
Bms-816336 SCHEMBL13216205 0.83 HSD11B1 (1.00) HSD11B1
SCHEMBL13216447 0.81 HSD11B1 (0.69) HSD11B1
SCHEMBL13238100 0.78 HSD11B1 (0.76) HSD11B1
SCHEMBL13317402 0.77 HSD11B1 (0.70) HSD11B1
SCHEMBL13317386 0.77 HSD11B1 (0.84) HSD11B1
SCHEMBL13216454 0.77 HSD11B1 (0.81) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054368-B1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-09-16 EP disclosed
US-8299054-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-30 US disclosed
US-8299054-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-30 US disclosed
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-7727978-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
US-7727978-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-09-25 US disclosed
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-09-25 US disclosed
WO-2008024892-A2 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.